EyePoint DURAVYU LUGANO trial misses primary endpoint; secondary endpoints strong

EyePoint, Inc.

Primary endpoint not met in full dataset; ad hoc analysis excluding 4% asymmetric cohort (9/211) showed non-inferiority to aflibercept (p=0.0096).
42% reduction in treatment burden vs aflibercept (p<0.0001); 76% supplement-free to Week 32, 54% to Week 56.
79% of DURAVYU patients received 0 or 1 supplement up to Week 56; supplement-free BCVA non-inferior (p=0.0035).
LUCIA topline expected Q4 2026; NDA filing planned 1H 2027; DME trials COMO/CAPRI topline Q4 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.